Systematic review demonstrates lower dementia risk in patients using SGLT2 inhibitors compared to DPP-4 inhibitors, suggesting potential therapeutic advantages.
Use of SGLT2 inhibitors is significantly associated with lower dementia risk compared to DPP-4 inhibitors in patients with T2DM. Prospective trials are warranted to confirm these findings and explore underlying mechanisms.
No takes yet. Share an insight, caveat, or question.
Kumari et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: